Enclomiphene is an oral selective estrogen receptor modulator developed for the management of secondary hypogonadism and testosterone deficiency in men. Unlike conventional testosterone replacement therapy, it stimulates the body's natural testosterone production pathway and is increasingly recognized for its potential role in fertility-preserving hormone restoration. Polaris Market Research estimates the global enclomiphene market at USD 213.9 million in 2025 and projects it to reach USD 445.8 million by 2034, a CAGR of 8.5% over 2026–2034, with North America the largest market in 2025.

Rising Diagnosis Supports Demand

Increasing cases of male hypogonadism are a core growth driver. Citing the Endocrine Society, the report notes that male hypogonadism is observed in almost 35% of men older than 45 and in about 30–50% of men with obesity and type 2 diabetes. Rising incidence of secondary hypogonadism, testosterone deficiency and andropause is increasing the need for alternative treatments that raise testosterone levels without affecting fertility. Growing awareness of men's reproductive health, rising rates of obesity-linked hormonal conditions and the trend toward late parenthood add further momentum, alongside the expansion of digital healthcare services.

The Fertility Preservation Opportunity

The most promising opportunity lies in fertility-preserving testosterone restoration. Male patients who need hormone restoration are becoming more concerned about fertility outcomes alongside symptomatic relief, and demand from fertility clinics, reproductive centers and men's health centers is projected to drive future growth. Secondary hypogonadism held a 56.7% revenue share by indication in 2025, as enclomiphene's ability to induce natural testosterone production makes it an attractive option for men seeking an alternative to conventional therapy. Premium insights place the most promising opportunity at the intersection of fertility preservation, digital men's health services and oral hormone restoration therapies. Male infertility support is projected to register the highest CAGR among indications, owing to increasing awareness of reproductive health issues and delayed parenthood.

Browse More Information:

https://www.polarismarketresearch.com/industry-analysis/enclomiphene-market 

Alternatives and Regulatory Uncertainty

The trend toward alternatives to testosterone replacement therapy is a recurring theme in the report, with oral products compared against traditional forms and tailored hormone management programs identified among key growth opportunities. Regulatory uncertainty is the main restraint: the lack of FDA approval for enclomiphene in the US continues to be an important issue for players, and regulatory hurdles affect business plans and investment opportunities. Companies that look only at rising patient need and overlook other factors may face commercialization difficulties.

Regional Outlook

North America dominated with a 51.3% revenue share in 2025 owing to higher awareness of testosterone deficiency, adoption of men's health treatments and developed telemedicine systems. In April 2026, the US Food and Drug Administration increased efforts around testosterone deficiency awareness and the evaluation and treatment of men with low testosterone and idiopathic hypogonadism. Europe was the second leading market, and the 28th European Congress of Endocrinology in Prague in May 2026 brought specialists together to discuss testosterone deficiencies in men and men's reproductive health. Asia Pacific is projected to grow fastest, at a CAGR of 9.2%, and in May 2026 Nova IVF Fertility acquired Craft Fertility and announced plans for ten more fertility clinics in Kerala, India. Latin America and the Middle East & Africa are expected to see stable to gradual growth on rising healthcare investment.

Key Players

• Aurobindo Pharma Limited
• Hetero Labs Limited
• Lupin Limited
• Maneesh Pharmaceuticals Limited
• Repros Therapeutics Inc.
• Sandoz International GmbH
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Limited
• Viatris Inc.
• Willow Birch Pharma, Inc.
• Zydus Lifesciences Limited
• Accord Healthcare PLC

Competition is based on treatment availability, product quality, partnership with physicians, patient support services and digital health care, and participants are focusing on treatment personalization and patient engagement strategies to strengthen their market position.

Conclusion

Demand for enclomiphene is tied to better diagnosis of male hormonal conditions and growing interest in therapies that protect fertility. While regulatory uncertainty in the US remains a hurdle, rising awareness of male reproductive health and fertility-focused demand support the outlook through 2034.

More Trending Latest Reports By Polaris Market Research:

5G Fixed Wireless Access Market

Medical Tourism Market

Food Fortifying Agents Market

Continuous Glucose Monitoring Device Market

Protein A, G and L Resins Market

Disaster Recovery as a Service Market

Disaster Recovery as a Service Market

Food Fortifying Agents Market

Fetal Bovine Serum Market